Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$16M 391.9%
Total revenue, Q2 '26 (USD).

Did Foghorn Therapeutics Beat Earnings?

Foghorn Therapeutics (FHTX) reported Q2 '26 revenue of $16M, up 112.7% year-over-year.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Foghorn Therapeutics’s job postings, web traffic, and employee business outlook. See the full FHTX stock analysis or the earnings calendar for upcoming reports.

Foghorn Therapeutics Quarterly Financial Trends (USD)

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue7.8M2.9M6M7.6M8.2M9.2M3.3M16M
Gross margin100.0%100.0%100.0%88.1%-145.3%91.3%92.7%100.0%
Operating margin-305.5%-840.5%-385.0%-279.2%-226.9%-211.9%-660.3%-54.8%
Net income-19M-20M-19M-18M-16M-22M-20M-7.2M
Net margin-244.9%-682.9%-316.4%-237.3%-194.4%-234.3%-608.4%-44.7%
EPS————————

Foghorn Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Foghorn Therapeutics’s quarterly revenue moved from $7.8M to $16M. Net margin expanded from -244.9% to -44.7%, against a 100% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is Foghorn Therapeutics’s Next Earnings Date?

Foghorn Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the FHTX earnings calendar.

Frequently Asked Questions: Foghorn Therapeutics Earnings

Foghorn Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Foghorn Therapeutics reported Q2 '26 revenue of $16M, up 112.7% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the FHTX AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.